Since IL-18 has recently emerged as a biomarker associated with refractory disease course in SJIA, the focus of the discussion was the feasibility of the biomarker-driven drug development to SJIA. Overall, there was broad agreement on the conclusion that IL-18 is a uniquely specific biomarker for many of the subsets of SJIA most in need of new therapies, and it may define a class of diseases mediated by IL-18 excess. The consensus was that leveraging IL-18 remains our most promising “lead” for use in refractory SJIA as it may mechanistically explain the disease pathophysiology and lead to more targeted therapies.

中文翻译：

---

SJIA 和 MAS 的第四次 NextGen 疗法，第 4 部分：是时候进行基于 IL-18 的系统性幼年特发性关节炎试验了？

由于IL-18最近成为与SJIA难治性病程相关的生物标志物，讨论的焦点是生物标志物驱动的SJIA药物开发的可行性。总体而言，人们普遍同意以下结论：IL-18 是许多最需要新疗法的 SJIA 亚型的独特特异性生物标志物，并且它可能定义一类由 IL-18 过量介导的疾病。一致认为，利用 IL-18 仍然是我们治疗难治性 SJIA 最有希望的“先导”，因为它可以从机制上解释疾病的病理生理学并导致更有针对性的治疗。